Dr. Castillo on the Use of Venetoclax in Waldenstrom Macroglobulinemia
September 15th 2019Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of a multicenter, prospective, phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia.
Read More
Dr. Castillo on Emerging Treatment Approaches in Waldenstrom Macroglobulinemia
August 14th 2019Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, highlights ongoing research with emerging treatment approaches in Waldenström macroglobulinemia.
Read More